Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of ...

3 August 2026 · By · Wire by Fusion42

Published

3 August 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at investor.lilly.com →

◆ Verified

Fusion42 · 4 August 2026 · Fusion42 review

The U.S. FDA has granted Breakthrough Therapy designation to Eli Lilly's olomorasib as a monotherapy for previously treated adult patients with advanced pancreatic cancer having the KRAS G12C mutation, aiming to expedite its development and review.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a faster path to market if you work on targeted therapies for KRAS G12C pancreatic cancer, as FDA now signals urgency to support innovations in this hard-to-treat cancer. This designation cuts development friction and positions you to compete in a currently underserved patient population.

◆ Coverage

1 source · 3 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfdabreakthrough-therapypancreatic-cancerkras-g12concologydrug-development